RecruitingNCT04367883

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection

Sponsor

Consorci Sanitari de Terrassa

Enrollment

3,000 participants

Start Date

Mar 1, 2020

Study Type

OBSERVATIONAL

Conditions

COVID19 Influenza vaccination ARB Amantadine ACE Inhibitors Antihistamine Allergy

Summary

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is looking at whether having received a flu vaccine, or taking blood pressure medications called ACE inhibitors (ACEIs) or ARBs, affected how severely patients were affected by COVID-19. Early in the pandemic, there was debate about whether these very common medications might make COVID-19 worse or better. This study uses hospital admission records to investigate. Researchers analysed data from patients admitted to Terrassa Hospital in Spain from March 2020 onward to compare vaccination and medication patterns against outcomes. The study helps clarify whether routine medications like ACEIs and ARBs — taken by millions worldwide — have any meaningful effect on COVID-19 severity. You may be eligible if: - You were admitted to Terrassa Hospital from March 1, 2020 for any reason You may NOT be eligible if: - You live outside the Terrassa Health Consortium's reference area (for the comparison sub-analysis with the general population) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.